{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:47:18Z","timestamp":1792734438190,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31DK138790-01"],"award-info":[{"award-number":["F31DK138790-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HG012928"],"award-info":[{"award-number":["R01HG012928"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM143068"],"award-info":[{"award-number":["R35GM143068"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK131492"],"award-info":[{"award-number":["R01DK131492"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04097-4","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:24:24Z","timestamp":1764728664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types"],"prefix":"10.1007","volume":"17","author":[{"given":"Mario M.","family":"Alba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry S. H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangyan","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-3703","authenticated-orcid":false,"given":"Hagai","family":"Ligumsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"4097_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.615375","volume":"10","author":"T Scully","year":"2020","unstructured":"Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, Type 2 Diabetes, and Cancer Risk. Front Oncol. 2020;10:615375.","journal-title":"Front Oncol"},{"key":"4097_CR2","doi-asserted-by":"publisher","first-page":"155217","DOI":"10.1016\/j.metabol.2022.155217","volume":"133","author":"C Boutari","year":"2022","unstructured":"Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217.","journal-title":"Metabolism"},{"key":"4097_CR3","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"issue":"2","key":"4097_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","volume":"6","author":"MM Veniant","year":"2024","unstructured":"Veniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290\u2013303.","journal-title":"Nat Metab"},{"issue":"6","key":"4097_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"4097_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409\u201339.","journal-title":"Physiol Rev"},{"issue":"6","key":"4097_CR7","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1210\/en.2004-0015","volume":"145","author":"PL Brubaker","year":"2004","unstructured":"Brubaker PL, Drucker DJ, Minireview. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145(6):2653\u20139.","journal-title":"Endocrinology"},{"issue":"12","key":"4097_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"24","key":"4097_CR9","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"9","key":"4097_CR10","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/STROKEAHA.121.037775","volume":"53","author":"WD Strain","year":"2022","unstructured":"Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, Rothwell PM, et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022;53(9):2749\u201357.","journal-title":"Stroke"},{"issue":"5","key":"4097_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-8587(17)30109-2","volume":"5","author":"N Katsiki","year":"2017","unstructured":"Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol. 2017;5(5):329\u201330.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"4097_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","volume":"358","author":"Y Wei","year":"1995","unstructured":"Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358(3):219\u201324.","journal-title":"FEBS Lett"},{"issue":"4","key":"4097_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1471-4159.2004.02914.x","volume":"92","author":"E Alvarez","year":"2005","unstructured":"Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem. 2005;92(4):798\u2013806.","journal-title":"J Neurochem"},{"issue":"5","key":"4097_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","volume":"48","author":"M Korner","year":"2007","unstructured":"Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48(5):736\u201343.","journal-title":"J Nucl Med"},{"issue":"4","key":"4097_CR15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473\u201386.","journal-title":"Endocrinology."},{"issue":"2","key":"4097_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 receptor agonists and colorectal cancer risk in Drug-Naive patients with type 2 Diabetes, with and without Overweight\/Obesity. JAMA Oncol. 2024;10(2):256\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4097_CR17","doi-asserted-by":"publisher","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024;7(1):e2350408.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"4097_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12032-024-02390-w","volume":"41","author":"H Ligumsky","year":"2024","unstructured":"Ligumsky H, Amir S, Arbel Rubinstein T, Guion K, Scherf T, Karasik A, et al. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells. Med Oncol. 2024;41(6):138.","journal-title":"Med Oncol"},{"issue":"9","key":"4097_CR19","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1210\/en.2011-1201","volume":"152","author":"JA Koehler","year":"2011","unstructured":"Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. 2011;152(9):3362\u201372.","journal-title":"Endocrinology"},{"issue":"10","key":"4097_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.31083\/j.fbl2810259","volume":"28","author":"Z Pu","year":"2023","unstructured":"Pu Z, Yang Y, Qin S, Li X, Cui C, Chen W. The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage. Front Biosci (Landmark Ed). 2023;28(10):259.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"9","key":"4097_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/dom.12291","volume":"16","author":"H Zhao","year":"2014","unstructured":"Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J, et al. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway. Diabetes Obes Metab. 2014;16(9):850\u201360.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4097_CR22","first-page":"91","volume":"125","author":"XN Li","year":"2017","unstructured":"Li XN, Bu HM, Ma XH, Lu S, Zhao S, Cui YL, et al. Glucagon-like Peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro. Exp Clin Endocrinol Diabetes. 2017;125(2):91\u20137.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"4097_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.mce.2016.07.032","volume":"436","author":"W He","year":"2016","unstructured":"He W, Yu S, Wang L, He M, Cao X, Li Y, et al. Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells. Mol Cell Endocrinol. 2016;436:240\u20139.","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"4097_CR24","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/en.2017-00461","volume":"158","author":"C Iwaya","year":"2017","unstructured":"Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, et al. Exendin-4, a glucagonlike Peptide-1 receptor Agonist, attenuates breast cancer growth by inhibiting NF-kappaB activation. Endocrinology. 2017;158(12):4218\u201332.","journal-title":"Endocrinology"},{"key":"4097_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120370","volume":"294","author":"ZZ Liu","year":"2022","unstructured":"Liu ZZ, Duan XX, Yuan MC, Yu J, Hu X, Han X, et al. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4\/ROS\/VEGF pathway. Life Sci. 2022;294:120370.","journal-title":"Life Sci"},{"issue":"3","key":"4097_CR26","first-page":"209","volume":"42","author":"H Wenjing","year":"2017","unstructured":"Wenjing H, Shuang Y, Weisong L, Haipeng X. Exendin-4 does not modify growth or apoptosis of human colon cancer cells. Endocr Res. 2017;42(3):209\u201318.","journal-title":"Endocr Res"},{"issue":"1","key":"4097_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2023.2301324","volume":"44","author":"W Li","year":"2024","unstructured":"Li W, Lyu W, Liu S, Ruan F, Zhang X. GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death. J Obstet Gynaecol. 2024;44(1):2301324.","journal-title":"J Obstet Gynaecol"},{"issue":"3","key":"4097_CR28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3892\/or.2015.4476","volume":"35","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Xu F, Liang H, Cai M, Wen X, Li X, et al. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice. Oncol Rep. 2016;35(3):1340\u20138.","journal-title":"Oncol Rep"},{"issue":"4","key":"4097_CR29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3803\/EnM.2014.29.4.536","volume":"29","author":"MJ Jung","year":"2014","unstructured":"Jung MJ, Kwon SK. Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance. Endocrinol Metab (Seoul). 2014;29(4):536\u201344.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"11","key":"4097_CR30","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2337\/db13-1169","volume":"63","author":"T Nomiyama","year":"2014","unstructured":"Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63(11):3891\u2013905.","journal-title":"Diabetes"},{"issue":"D1","key":"4097_CR31","doi-asserted-by":"publisher","first-page":"D1082","DOI":"10.1093\/nar\/gkad987","volume":"52","author":"BJ Raney","year":"2024","unstructured":"Raney BJ, Barber GP, Benet-Pages A, Casper J, Clawson H, Cline MS, et al. The UCSC genome browser database: 2024 update. Nucleic Acids Res. 2024;52(D1):D1082\u20138.","journal-title":"Nucleic Acids Res"},{"key":"4097_CR32","doi-asserted-by":"crossref","unstructured":"Uhlen M, Karlsson MJ, Hober A, Svensson AS, Scheffel J, Kotol D, et al. The human secretome. Sci Signal. 2019;12(609).","DOI":"10.1126\/scisignal.aaz0274"},{"issue":"6","key":"4097_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"4097_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580\u20135.","journal-title":"Nat Genet"},{"issue":"5","key":"4097_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"1","key":"4097_CR36","doi-asserted-by":"publisher","first-page":"170113","DOI":"10.1038\/sdata.2017.113","volume":"4","author":"H Kawaji","year":"2017","unstructured":"Kawaji H, Kasukawa T, Forrest A, Carninci P, Hayashizaki Y. The FANTOM5 collection, a data series underpinning mammalian transcriptome atlases in diverse cell types. Sci Data. 2017;4(1):170113.","journal-title":"Sci Data"},{"issue":"5","key":"4097_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"3","key":"4097_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413\u201331.","journal-title":"Cell"},{"issue":"9","key":"4097_CR39","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc2399","volume":"8","author":"DL Burkhart","year":"2008","unstructured":"Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4097_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","volume":"133","author":"L Salmena","year":"2008","unstructured":"Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403\u201314.","journal-title":"Cell"},{"issue":"1","key":"4097_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22\u201335.","journal-title":"Cell"},{"issue":"Suppl 4","key":"4097_CR42","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","volume":"37","author":"RI Nicholson","year":"2001","unstructured":"Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9\u201315.","journal-title":"Eur J Cancer"},{"issue":"4","key":"4097_CR43","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","volume":"1768","author":"JM Busillo","year":"2007","unstructured":"Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta. 2007;1768(4):952\u201363.","journal-title":"Biochim Biophys Acta"},{"key":"4097_CR44","first-page":"1347","volume":"6","author":"M Cojoc","year":"2013","unstructured":"Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis. Onco Targets Ther. 2013;6:1347\u201361.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"4097_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/labinvest.3700208","volume":"85","author":"JB de Kok","year":"2005","unstructured":"de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005;85(1):154\u20139.","journal-title":"Lab Invest"},{"issue":"6","key":"4097_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0009-9120(93)80007-H","volume":"26","author":"MJ Duffy","year":"1993","unstructured":"Duffy MJ. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin Biochem. 1993;26(6):439\u201347.","journal-title":"Clin Biochem"},{"issue":"7463","key":"4097_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"10","key":"4097_CR48","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1210\/me.2011-1160","volume":"25","author":"K Coopman","year":"2011","unstructured":"Coopman K, Wallis R, Robb G, Brown AJ, Wilkinson GF, Timms D, et al. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor. Mol Endocrinol. 2011;25(10):1804\u201318.","journal-title":"Mol Endocrinol"},{"issue":"10","key":"4097_CR49","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s42255-023-00889-6","volume":"5","author":"W Gao","year":"2023","unstructured":"Gao W, Liu L, Huh E, Gbahou F, Cecon E, Oshima M, et al. Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity. Nat Metab. 2023;5(10):1673\u201384.","journal-title":"Nat Metab"},{"issue":"10","key":"4097_CR50","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The cancer genome atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113\u201320.","journal-title":"Nat Genet"},{"issue":"3","key":"4097_CR51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","volume":"6","author":"FX Schaub","year":"2018","unstructured":"Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, et al. Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas. Cell Syst. 2018;6(3):282\u2013300. e2.","journal-title":"Cell Syst"},{"issue":"1","key":"4097_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2018.03.046","volume":"23","author":"GP Way","year":"2018","unstructured":"Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, et al. Machine learning detects Pan-cancer Ras pathway activation in the cancer genome atlas. Cell Rep. 2018;23(1):172\u201380. e3.","journal-title":"Cell Rep"},{"issue":"7","key":"4097_CR53","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7):e2421305.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"4097_CR54","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","volume":"132","author":"H Ligumsky","year":"2012","unstructured":"Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat. 2012;132(2):449\u201361.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4097_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L","volume":"172","author":"C Montrose-Rafizadeh","year":"1997","unstructured":"Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol. 1997;172(3):275\u201383.","journal-title":"J Cell Physiol"},{"issue":"1","key":"4097_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1677\/joe.0.1460183","volume":"146","author":"ML Villanueva-Penacarrillo","year":"1995","unstructured":"Villanueva-Penacarrillo ML, Delgado E, Trapote MA, Alcantara A, Clemente F, Luque MA, et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol. 1995;146(1):183\u20139.","journal-title":"J Endocrinol"},{"issue":"9","key":"4097_CR57","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1055\/s-0030-1253421","volume":"42","author":"E Tomas","year":"2010","unstructured":"Tomas E, Stanojevic V, Habener JF. GLP-1 (9\u201336) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res. 2010;42(9):657\u201362.","journal-title":"Horm Metab Res"},{"issue":"7","key":"4097_CR58","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","volume":"137","author":"BP Bullock","year":"1996","unstructured":"Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968\u201378.","journal-title":"Endocrinology"},{"issue":"2","key":"4097_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tem.2009.11.007","volume":"21","author":"E Tomas","year":"2010","unstructured":"Tomas E, Habener JF. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab. 2010;21(2):59\u201367.","journal-title":"Trends Endocrinol Metab"},{"issue":"6447","key":"4097_CR60","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/365649a0","volume":"365","author":"J Parma","year":"1993","unstructured":"Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, et al. Somatic mutations in the Thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 1993;365(6447):649\u201351.","journal-title":"Nature"},{"issue":"6","key":"4097_CR61","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrc3521","volume":"13","author":"M O'Hayre","year":"2013","unstructured":"O\u2019Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer. 2013;13(6):412\u201324.","journal-title":"Nat Rev Cancer"},{"key":"4097_CR62","doi-asserted-by":"crossref","unstructured":"Liu Y, Beyer A, Aebersold R. On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell. 2016;165(3):535-50.","DOI":"10.1016\/j.cell.2016.03.014"},{"key":"4097_CR63","doi-asserted-by":"crossref","unstructured":"Barker AD, Alba MM, Mallick P, Agus DB, Lee JSH. An Inflection Point in Cancer Protein Biomarkers: What was and What's Next. Molecular & Cellular Proteomics. 2023;22(7).","DOI":"10.1016\/j.mcpro.2023.100569"},{"issue":"9","key":"4097_CR64","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41588-024-01785-9","volume":"56","author":"B Kinnersley","year":"2024","unstructured":"Kinnersley B, Sud A, Everall A, Cornish AJ, Chubb D, Culliford R, et al. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. Nat Genet. 2024;56(9):1868\u201377.","journal-title":"Nat Genet"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04097-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:02:59Z","timestamp":1767794579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04097-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4097"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04097-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}